MAPT and Alzheimer disease: According to the recently proposed diagnostic criteria of AD, the preclinical AD stage is characterized by abnormal deposition of amyloid-β in the brain, as well as by a reduction of Aβ42 and increased phospho-tau in the cerebrospinal fluid (CSF) (Dubois et al., 2014).